Copyright © 2021. Inderes Oyj. All rights reserved.

Redeye comments on the positive opinion of the Committee for Orphan Medicinal Products concerning an orphan designation of nadunolimab in pancreatic cancer from yesterday. This news follows on the orphan drug designation from the FDA last month. Nadunolimab will now have orphan drug designation in pancreatic cancer in the two major regulatory areas in the world (after the final approval from EMA, expected within 30 days). The orphan drug designation in the EU is similar to the US one. We refer to our last note for more details. A major difference is the longer duration of the market exclusivity, which is 10 years in the EU.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.